Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, March 18th.

Can-Fite BioPharma Price Performance

CANF stock opened at $1.60 on Friday. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The company has a 50-day moving average of $1.59 and a two-hundred day moving average of $1.87. The stock has a market capitalization of $5.66 million, a price-to-earnings ratio of -0.89 and a beta of 1.12.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma at the end of the most recent quarter. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.